Andriukaitis: Supporting drug innovation is ‘the only way’

Expert: "The IP aims to give certain exclusivity rights, it’s a stimulus to innovate and develop new products and the basic idea is that you can get a good financial return on innovation efforts." [European Commission]

This article is part of our special report Pharma innovation.

Backing innovation in the pharmaceutical market and developing new evidence-based economic models is the only way forward for future healthcare, according to EU Commissioner for Health and Food Safety Vytenis Andriukaitis. reports from Austria.

Hit hard by austerity, the health systems of EU member states are under huge pressure. Combined with an ageing population and the alarming burden of chronic illnesses, EU member states have targeted specific aspects of the incentives granted to the pharma industry in order to decrease drug prices.

On the other hand, many suggest that such an approach would have a detrimental impact on innovation in the pharma sector. Instead, they claim policymakers should focus on other healthcare fields to save costs, considering that the pharmaceutical expenditure has remained stable in recent years.

Incentivising innovation

Member states have the full competence to decide which medicinal products are reimbursed and at what price, while the European Commission is exclusively responsible for the competition of medicinal products on the EU market.

In June 2016, EU health ministers called on the European Commission to perform an overview of the current EU legislative tools and incentives that aim to facilitate investment in the development of medicinal products.

One of these incentives is the supplementary protection certificates (SPCs), an intellectual property right that serves as an extension of a patent right. The regular patent for a pharmaceutical product in the EU is 20 years. An SPC can extend this patent right for a maximum of five years.

Gastein boss: Drugs access is ‘sensitive’ and cannot be viewed in isolation

Accessibility of medicines is a sensitive issue that must not be examined in isolation. Policymakers, academics, business and patients must be part of the discussion as well as “innovation” because access would not get the focus it needs without it, according to Dorli Kahr-Gottlieb.

Specifically, SPCs aim to offset the loss of patent protection for pharmaceutical products that occurs due to the compulsory lengthy testing and clinical trials these products require prior to obtaining regulatory marketing approval. This period can last 12 years.

Speaking to EURACTIV on the sidelines of the European Health Forum Gastein (EHFG) in Austria last week (4-6 October) Andriukaitis said there was a need to understand innovation.

“It’s a very broad understanding as we have a lot of different innovations that we need to develop new economic models,” he said.

Asked whether a shift in incentives should still support innovation he replied, “No doubt. We need to discuss issues in complexity. Some incentives are old; some mechanisms need to be developed.”

“There is only one way, to support innovations and use evidence-based economic models,” Andriukaitis said, adding that “justice” is needed in the revision of patent issues and SPCs.

The EU health chief stressed that the executive was open on how to move forward collecting all data and pointed out that next year would be a good opportunity to debate different ideas.

Without incentives, innovation stops

In a separate interview with EURACTIV, Nathalie Moll, director-general at the European Federation of Pharmaceutical Industries and Associations (EFPIA), said incentives are the “foundation” on which all medical innovation is based.

“It’s what gives investors and innovators the confidence to take that moonshot, open up a new treatment pathway, deliver the next piece of incremental innovation then navigate the long, complex and risky road to bring a new treatment to patients,” she said.

“Without incentives, innovation stops,” she warned, adding that a possible devaluation could lead to €33 billion investment in research and development moving away from Europe.

Asked about SPCs, Moll noted that the European framework of incentives is an interlinked package of measures that work together.

“Devalue any aspects of the framework and it has a negative impact on innovation and makes Europe a less attractive place to innovate,” she said, adding that SPCs were created to make up for the incredibly long development and regulatory processes medicines go through.

Pharma boss: Targeting drugs won’t make healthcare systems more sustainable

“Salami-slicing” the cost of medicines, which represent almost one-fifth of health system budgets and are subject to rigorous value assessments, won’t make healthcare systems more sustainable in the future, Nathalie Moll told in an interview.

Don’t attack the innovation system

Peter Bogaert, a specialist in life sciences and partner with the law firm Covington & Burling, shares a similar view.

“The incentives which are built in the pharmaceutical regime and especially the SPCs and the regulatory exclusivity aim to work as a stimulus to develop new products in order to basically continue the innovation in the long term,” he told EURACTIV.

Bogaert admitted that there might be models where one has a more fine-tuned approach to the prices but one should not attack the innovation system purely in order to get cheaper products because then “you are undermining the incentives for new products and this reduces the level of innovation in the industry”.

“The IP aims to give certain exclusivity rights, it’s a stimulus to innovate and develop new products and the basic idea is that you can get a good financial return on innovation efforts,” he emphasised.

In addition, there are voices suggesting a moderate solution that will ultimately favour public health. An EU diplomat told EURACTIV in Brussels that a “consensus” was possible considering that all stakeholders on the table will have their ears open.

“We neither can fully accept the public health NGOs arguments about incentives nor fully disregard the pharma industry concerns about innovation […] practically we are talking about patients and it’s their life at stake,” the diplomat explained, adding that the pharma industry should “no way” be discouraged from innovating.

IP not linked to innovation

Following a request by the EU Council, the European Commission is currently doing a review of the incentives and by the end of this year or in the beginning of next year it’s expected to come up with a study.

Clemens Martin Auer, EHFG President and Director General at the Austrian Federal Ministry of Health and Women’s Affairs, said it was unprecedented that the EU health ministers should ask the Commission to do something like that.

“Because the ministers are concerned that there might be disincentives in the market regarding certain aspects of the IP (intellectual property) regulation, not the IP regulation in general. This is a misunderstanding in the public discussion that some pharmaceutical representatives are doing, maybe on purpose,” he said.

Auer added that not only the Commission but OECD and WHO are doing it as well

“Because if one looks deeply into this issue, one will find out that IP, in general, is not always linked to innovation. IP is about granting market exclusivity and this is a totally different topic than innovation. It has to be a balanced approach,” he emphasised.

‘We need affordability at the end of the day’

Dr Suerie Moon, a Research Director and Co-Chair of the Forum on Global Governance for Health at the Harvard Global Health Institute, does not share the pharma industry’s concerns.

Dr Moon highlighted the “fear” of policymakers to touch on IP systems, claiming that if a system is not delivering the outcomes society wants, then that policy needs to change.

She told EURACTIV that the current tools, including the IP system, were very “blunt, not well calibrated to get certain types of innovation”.

“That’s, for example, why we don’t have any new classes of antibiotics,” she stated, adding that policymakers need to figure out the right mix of incentives and regulations that would generate both the innovations that society needs as well as ensuring that they are affordable.

For Dr Moon, patents can be licensed to multiple suppliers, so it is not a question of patents or no patents. “But if a firm has a patent on a medicine, the government could conduct a patent buy out – the idea is that the government gives a prize to the firm, because the firm has developed a useful new product, and in exchange the government is able to purchase the medicine at the generic price,” she noted citing as an example Australia with hepatitis C.

Subscribe to our newsletters